China's OneX raises tens of millions of yuan in Series A for life-science AI
What's the deal? OneXDealroom has a profile for this one. Try Dealroom → Intelligence, a Chinese AI4S startup founded in 2025, has raised tens of millions of yuan in a Series A round, it announced in November 2026. The investors were not disclosed.
What's the endgame? The company builds a multi-agent evidence-based reasoning engine and a life-science large model. Its stated aim is to make rare-disease diagnosis, drug discovery, and clinical decisions more traceable and verifiable.
What's the money for? OneX will use the funding to iterate its core model, expand its team, and run clinical-scenario validation.
Why now? The round lands as funding for AI in science and drug development heats up in China. AI-pharma deals totalled US$2.17B in the first nine months of 2026, though the four largest accounted for roughly 60% of that.
The signal: Investor attention is shifting from model narratives toward experimental proof, clinical value, and commercial use. With OneX's backers and exact amount undisclosed and no results yet reported, the round reads as an early bet on a hot sector rather than proof of a breakthrough — and its claimed traceable, verifiable capabilities still need validation in real diagnostic or research settings.
Read more: itjuzi.com
Image credit: jurvetson
